Literature DB >> 15899935

Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients.

Angela Yee-Moon Wang1, Jean Woo, Christopher Wai-Kei Lam, Mei Wang, Iris Hiu-Shuen Chan, Ping Gao, Siu-Fai Lui, Philip Kam-Tao Li, John E Sanderson.   

Abstract

BACKGROUND: Fetuin-A (alpha2-Heremans Schmid glycoprotein) has recently been identified as a circulating inhibitor of calcification and is regulated as a negative acute phase protein. However, its relationships with cardiac valvular calcification and atherosclerosis and outcome have not been evaluated in peritoneal dialysis (PD) patients.
METHOD: We performed a prospective follow-up study in 238 PD patients with echocardiography done at baseline to detect cardiac valvular calcification and biochemical analysis performed for serum fetuin-A, albumin and C-reactive protein (CRP).
RESULTS: Baseline serum fetuin-A concentration was (mean+/-SD) 0.309+/-0.068 g/l (normal range 0.4-0.95). Across the three tertiles of increasing serum fetuin-A, a significant trend effect was observed for age (P = 0.023), diabetes (P = 0.008), background atherosclerotic vascular disease (P = 0.010), cardiac valvular calcification (P = 0.002), serum albumin (P<0.001), subjective global assessment (P = 0.005) and CRP (P<0.001). Adjusting for CRP and calcium x phosphorus product, every 0.01 g/l increase in serum fetuin-A remained independently associated with a 6% decrease in the risk of valvular calcification (95% confidence intervals, 0.90-0.99; P = 0.028). Furthermore, serum fetuin-A showed a significant decrease across the four groups of patients with increasing components of the malnutrition, inflammation, atherosclerosis/calcification (MIAC) syndrome (P<0.001) and was the lowest among patients with all components of the MIAC syndrome (0.263+/-0.055 g/l) and highest among those who do not have the MIAC syndrome at all (0.338+/-0.063 g/l). Lower serum fetuin-A was associated with greater all-cause mortality (P = 0.0011) and fatal and non-fatal cardiovascular events (P = 0.0017), but its significance was lost when atherosclerotic vascular disease, valvular calcification, inflammation and malnutrition were included in the model.
CONCLUSIONS: Serum fetuin-A showed important associations with valvular calcification, atherosclerosis, malnutrition and inflammation, and was linked to mortality and cardiovascular events in PD patients via its close relationships with the MIAC syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899935     DOI: 10.1093/ndt/gfh891

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  80 in total

1.  The relationship between epicardial adipose tissue and malnutrition, inflammation, atherosclerosis/calcification syndrome in ESRD patients.

Authors:  Kultigin Turkmen; Hatice Kayikcioglu; Orhan Ozbek; Yalcin Solak; Mehmet Kayrak; Cigdem Samur; Melih Anil; Halil Zeki Tonbul
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-14       Impact factor: 8.237

2.  The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

Authors:  Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix
Journal:  Ann Intern Med       Date:  2010-05-18       Impact factor: 25.391

Review 3.  Biomarkers of Calcific Aortic Valve Disease.

Authors:  Aeron Small; Daniel Kiss; Jay Giri; Saif Anwaruddin; Hasan Siddiqi; Marie Guerraty; Julio A Chirinos; Giovanni Ferrari; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-02-02       Impact factor: 8.311

Review 4.  Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease.

Authors:  János Nemcsik; István Kiss; András Tislér
Journal:  World J Nephrol       Date:  2012-02-06

5.  Biomarkers of vascular calcification and mortality in patients with ESRD.

Authors:  Julia J Scialla; W H Linda Kao; Ciprian Crainiceanu; Stephen M Sozio; Pooja C Oberai; Tariq Shafi; Josef Coresh; Neil R Powe; Laura C Plantinga; Bernard G Jaar; Rulan S Parekh
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

Review 6.  The role of fetuin-A in mineral trafficking and deposition.

Authors:  Michael M X Cai; Edward R Smith; Stephen G Holt
Journal:  Bonekey Rep       Date:  2015-05-06

7.  Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study.

Authors:  Jason P Linefsky; Kevin D O'Brien; Ronit Katz; Ian H de Boer; Eddy Barasch; Nancy S Jenny; David S Siscovick; Bryan Kestenbaum
Journal:  J Am Coll Cardiol       Date:  2011-07-12       Impact factor: 24.094

8.  Circulating calcification inhibitors and vascular properties in children after renal transplantation.

Authors:  Marieke J H van Summeren; Jeroen M Hameleers; Leon J Schurgers; Arnold P G Hoeks; Cuno S P M Uiterwaal; Thilo Krüger; Cees Vermeer; Wietse Kuis; Marc R Lilien
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

9.  Meta-analysis and profiling of cardiac expression modules.

Authors:  Uri David Akavia; Dafna Benayahu
Journal:  Physiol Genomics       Date:  2008-09-09       Impact factor: 3.107

10.  Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley
Journal:  Circulation       Date:  2007-05-07       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.